about
Pathway Processor 2.0: a web resource for pathway-based analysis of high-throughput dataFOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsWiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profilesAnalysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients.Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.Systems biology of host-mycobiota interactions: dissecting Dectin-1 and Dectin-2 signalling in immune cells with DC-ATLAS.Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia.Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsElectroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells.Mode of action of trabectedin in myxoid liposarcomas.MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy.A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.The orphan nuclear receptor COUP-TFII coordinates hypoxia-independent proangiogenic responses in hepatic stellate cells.Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature.IL-4-induced gene 1 maintains high Tob1 expression that contributes to TCR unresponsiveness in human T helper 17 cells.Role of Macrophage Targeting in the Antitumor Activity of TrabectedinExome sequencing in an Italian family with Alzheimer's disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615HBone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomesMusclin, A Myokine Induced by Aerobic Exercise, Retards Muscle Atrophy During Cancer Cachexia in MiceTranscriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric StudyMultisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.
P50
Q30641802-E95DD884-977F-4492-87EF-F597B845CC0BQ33651605-AA8CC105-DF3D-47F1-AA1C-5B1D425AEC96Q33791204-FA123F00-C9A1-45CB-B782-20D92013471BQ34025645-B615B685-4CFA-4137-8472-6855DF3616A2Q35595719-C20185B1-2723-4245-8770-5231EDD371E3Q36272148-8A94F65B-4E8E-4295-BEF2-2B20B6D3CCF9Q36381924-367FC7ED-5594-4A05-A5A2-1F2C03031F7FQ37702577-DC65FC82-3A90-421F-8139-0D421BE3B7BFQ38128038-5BB7BE79-12CB-4FEA-B092-0FBEEAA4F06EQ39065392-DCC05F4A-31A6-4823-8B17-76B09BEAA72FQ39106004-32E86867-33B9-42C4-BB79-D11DB57A4D52Q40091165-2630908A-7A61-4B99-9F18-698EFF6BD4F5Q41524895-ACAEFF11-8604-4964-BF3B-D00AF51CEA40Q43097170-C0B78823-783C-42FE-92CB-C19B05FF290EQ45346605-8065F67A-38DC-4420-8809-C633C2E72C75Q45915221-A3858CA9-D01A-487D-9801-562A6579D2A0Q46876939-B575C0CE-D0F7-478B-B2AE-50B332CD038FQ47855902-17CFF33A-F616-4802-8E5E-EF7C9BAC3153Q50858313-B4F6ACDB-9248-4761-8C76-47E89081CF21Q50860695-982183DE-6D79-48BF-8E93-01483E821439Q53671503-39E476BD-6BCB-4FCA-9AD4-2966553B40D0Q53748896-0BDA2148-6A4E-4620-ADAB-777E98BC6DCAQ54392412-35CE9D21-453F-4B80-B459-1D210B3FF79EQ56942258-1F5E0256-0C76-4250-840F-57E3533F5BD7Q57469898-FA05D6C2-D842-404B-B546-0483DA7C6142Q57787647-518FB2D5-FEFC-4E93-AB05-E4C8B64DCB36Q90722782-A2452D83-4D19-4265-8390-FF900425662EQ91727256-E9555C04-A6AD-4A99-91E9-A313D10993AAQ92500938-D852F554-29C4-4933-B944-433265A1566E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Luca Beltrame
@en
Luca Beltrame
@nl
type
label
Luca Beltrame
@en
Luca Beltrame
@nl
prefLabel
Luca Beltrame
@en
Luca Beltrame
@nl
P2002
P2037
P31
P496
0000-0003-3631-6544